The Cancer Letter

Inside information on cancer research and drug development

Vol.
9
No.
46
December 02, 1983Dec 02, 1983
Free
DOWNLOAD THE PDF

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

Workshop Calls For Improved Surgical Oncology Training Programs

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account